Evans syndrome future or investigational therapies: Difference between revisions
Created page with "__NOTOC__ {{Evans syndrome}} {{CMG}} ==Overview== ==Future or Investigational Therapies== In a patient with refractory disease, an allogeneic hematopoietic stem cell trans..." |
No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Evans syndrome}} | {{Evans syndrome}} | ||
{{CMG}} | {{CMG}} | ||
| Line 12: | Line 11: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | |||
[[Category:Hematology]] | |||
Latest revision as of 19:07, 15 June 2016
|
Evans syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Evans syndrome future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Evans syndrome future or investigational therapies |
|
Evans syndrome future or investigational therapies in the news |
|
Risk calculators and risk factors for Evans syndrome future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
In a patient with refractory disease, an allogeneic hematopoietic stem cell transplant (HSCT) resulted in complete clinical and serologic remission for more than 30 months. Allogeneic HSCT may be the only current curative therapy for Evans syndrome, but may also be complicated by significant toxicities. In more serious cases no cure exists.